Apyx Medical ( (APYX) ) has released its Q2 earnings. Here is a breakdown of the information Apyx Medical presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Apyx Medical Corporation is an advanced energy technology company specializing in helium plasma and radiofrequency platform technology, with products such as Renuvion and the AYON Body Contouring System in the cosmetic surgery market. The company also operates in the hospital surgical market with J-Plasma.
In its second quarter of 2025, Apyx Medical Corporation reported a decrease in total revenue to $11.4 million from $12.1 million in the same period last year. Despite this, the company successfully launched the AYON Body Contouring System to key surgeons and initiated commercial sales of Renuvion in China, leading to an increased revenue guidance for the full year.
Key financial highlights include a net loss reduction to $3.8 million from $6.6 million in the previous year, and a decrease in adjusted EBITDA loss to $2.0 million from $4.3 million. The company also achieved FDA clearance for AYON and reported strong interest in Renuvion in China, supported by a targeted sales campaign by its distribution partner.
Looking forward, Apyx Medical has revised its full-year revenue guidance upwards to $50.0 million to $52.0 million, reflecting confidence in its product launches and international expansion. The company aims to continue strengthening its market presence and driving growth in the aesthetic surgery sector.